Swami U - Search Results

1

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape.

Al-Akhras A, Hage Chehade C, Narang A, Swami U. Al-Akhras A, et al. Among authors: swami u. Life (Basel). 2024 Jan 30;14(2):198. doi: 10.3390/life14020198. Life (Basel). 2024. PMID: 38398706 Free PMC article. Review.

2

Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.

Mani S, Swami U. Mani S, et al. Among authors: swami u. Drugs Today (Barc). 2010 Sep;46(9):641-53. doi: 10.1358/dot.2010.46.9.1519020. Drugs Today (Barc). 2010. PMID: 20967296

3

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma.

Swami U, Swick B, Zakharia Y, Milhem M. Swami U, et al. Case Rep Oncol Med. 2019 Mar 7;2019:4683531. doi: 10.1155/2019/4683531. eCollection 2019. Case Rep Oncol Med. 2019. PMID: 30963012 Free PMC article.

4

Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.

Swami U, Agarwal N. Swami U, et al. Cancer Treat Res Commun. 2020;25:100205. doi: 10.1016/j.ctarc.2020.100205. Epub 2020 Aug 12. Cancer Treat Res Commun. 2020. PMID: 32822968 Free article.

5

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.

Rathi N, McFarland TR, Nussenzveig R, Agarwal N, Swami U. Rathi N, et al. Among authors: swami u. Drugs. 2021 Feb;81(2):191-206. doi: 10.1007/s40265-020-01456-z. Drugs. 2021. PMID: 33369720 Free PMC article. Review.

6

Current management of metastatic castration-sensitive prostate cancer.

Kessel A, Kohli M, Swami U. Kessel A, et al. Among authors: swami u. Cancer Treat Res Commun. 2021;28:100384. doi: 10.1016/j.ctarc.2021.100384. Epub 2021 Apr 24. Cancer Treat Res Commun. 2021. PMID: 33951556 Free article. Review.

7

Immune Checkpoint Inhibitors in Prostate Cancer.

Venkatachalam S, McFarland TR, Agarwal N, Swami U. Venkatachalam S, et al. Among authors: swami u. Cancers (Basel). 2021 May 2;13(9):2187. doi: 10.3390/cancers13092187. Cancers (Basel). 2021. PMID: 34063238 Free PMC article. Review.

8

Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations.

McFarland TR, Kessel A, Swami U, Agarwal N. McFarland TR, et al. Among authors: swami u. Am J Transl Res. 2021 Jul 15;13(7):7427-7439. eCollection 2021. Am J Transl Res. 2021. PMID: 34377227 Free PMC article. Review.

9

Recent Advances in the Management of Metastatic Prostate Cancer.

Sayegh N, Swami U, Agarwal N. Sayegh N, et al. Among authors: swami u. JCO Oncol Pract. 2022 Jan;18(1):45-55. doi: 10.1200/OP.21.00206. Epub 2021 Sep 2. JCO Oncol Pract. 2022. PMID: 34473525

10

Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.

Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U. Sayegh N, et al. Among authors: swami u. Eur Urol Focus. 2023 Jan;9(1):106-109. doi: 10.1016/j.euf.2022.06.015. Epub 2022 Jul 11. Eur Urol Focus. 2023. PMID: 35835693

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

116 results

Search Page